Show Summary Details

Page of

PRINTED FROM OXFORD HANDBOOKS ONLINE (www.oxfordhandbooks.com). © Oxford University Press, 2018. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Handbooks Online for personal use (for details see Privacy Policy and Legal Notice).

date: 22 March 2019

Abstract and Keywords

Progress in treating OCD has accelerated in recent years. Effective first-line treatments include behavior therapy and medications, with overwhelming evidence supporting the efficacy of serotonergic reuptake inhibitors (SRIs). Second-line medication treatments for OCD include augmentation of SRIs with neuroleptics, clonazepam, or buspirone, with limited support for other strategies at present. Alternative monotherapies (e.g., buspirone, clonazepam, phenelzine) have more limited supporting data and require further study. Behavior therapy, and perhaps cognitive therapy, is as effective as medication and may be superior in risks, costs, and enduring benefits. Future rigorous research is needed to determine which patients respond preferentially to which medications, at what dose, and after what duration. Emerging treatments include new compounds acting via serotonergic, dopaminergic, glutamatergic, and opioid systems.

Keywords: serotonergic reuptake inhibitors, SRI, SSRI, monotherapy, augmentation

Access to the complete content on Oxford Handbooks Online requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can''t find the answer there, please contact us.